Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-diabetic drugs and weight loss in patients with type 2 diabetes.
Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A, Montefusco L, Ippolito E, Berra C, D'Addio F, Zuccotti GV, Fiorina P. Lazzaroni E, et al. Pharmacol Res. 2021 Sep;171:105782. doi: 10.1016/j.phrs.2021.105782. Epub 2021 Jul 22. Pharmacol Res. 2021. PMID: 34302978 Free article.
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.
Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, Assi E, Seelam AJ, El Essawy B, Jang J, Loretelli C, D'Addio F, Berra C, Ben Nasr M, Zuccotti G, Fiorina P. Bendotti G, et al. Among authors: lazzaroni e. Pharmacol Res. 2022 Aug;182:106320. doi: 10.1016/j.phrs.2022.106320. Epub 2022 Jun 20. Pharmacol Res. 2022. PMID: 35738455 Review.
Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study.
Lazzaroni E, Lunati ME, Montefusco L, Pastore I, Chebat E, Cimino V, Morpurgo PS, Muratori M, Plebani L, Bolla A, Rossi A, Vallone L, Gandolfi A, Tinari C, D'Addio F, Nasr MB, Loretelli C, Scaranna C, Bellante R, Manfrini R, Muratori F, Franzetti I, Orsi E, Gazzaruso C, Ghelardi R, Desenzani P, Genovese S, Girelli A, Folli F, Berra C, Fiorina P. Lazzaroni E, et al. Pharmacol Res. 2022 Sep;183:106374. doi: 10.1016/j.phrs.2022.106374. Epub 2022 Jul 28. Pharmacol Res. 2022. PMID: 35908663
The anti-inflammatory and immunological properties of SGLT-2 inhibitors.
Bendotti G, Montefusco L, Pastore I, Lazzaroni E, Lunati ME, Fiorina P. Bendotti G, et al. Among authors: lazzaroni e. J Endocrinol Invest. 2023 Dec;46(12):2445-2452. doi: 10.1007/s40618-023-02162-9. Epub 2023 Aug 3. J Endocrinol Invest. 2023. PMID: 37535237 Review.
SARS-CoV-2-related atypical thyroiditis.
Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A, Ferrante E, Orsi E, Resi V, Longari V, Cuzzocrea M, Bandera A, Lazzaroni E, Dolci A, Ceriotti F, Re TE, Gori A, Arosio M, Salvi M. Muller I, et al. Among authors: lazzaroni e. Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741. doi: 10.1016/S2213-8587(20)30266-7. Epub 2020 Jul 30. Lancet Diabetes Endocrinol. 2020. PMID: 32738929 Free PMC article. No abstract available.
Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G, Covelli D, Campi I, Currò N, Dazzi D, Rodari M, Pepe G, Chiti A, Guastella C, Lazzaroni E, Salvi M. Vannucchi G, et al. Among authors: lazzaroni e. Thyroid. 2019 Dec;29(12):1828-1833. doi: 10.1089/thy.2019.0150. Thyroid. 2019. PMID: 31860407 Free article. Clinical Trial.
Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
Campi I, Vannucchi G, Muller I, Lazzaroni E, Currò N, Dainese M, Montacchini B, Covelli D, Guastella C, Pignataro L, Fugazzola L, Arosio M, Salvi M. Campi I, et al. Among authors: lazzaroni e. Front Endocrinol (Lausanne). 2022 Jan 25;12:790246. doi: 10.3389/fendo.2021.790246. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35145479 Free PMC article.
27 results